Please wait
HEALTHCARE · Pharmaceutical Preparations · Price, fundamentals, signals, and forward-looking context in one research view.
HEALTHCARE
₦225B
0.6%
31.18
Current price
₦56.20
Updated Updated 1h ago
Open
N/A
Previous close
₦56.20
Day range
N/A
Volume
908,755
31.2x P/E
Awaiting filing
0.6% yield
35/100 measured
Easy to trade
The latest saved price history for MECURE, with its range and direction at a glance.
Eye extracted 2 pages. Open the source or continue to Signals for the evidence trail.
Mecure Industries PLC manufactures and sells pharmaceuticals in Nigeria. The company engages in distributing multivitamins products. It also offers antibiotics, antimalarials, antihypertensives, antidiabetics, analgesics and nsaids, proton pump inhibitors, and H2 receptor antagonists. In addition, the company provides blood tonics; cough, cold, and catarrh preparations; antihistamines; anthelmintic; antacids; steroids; antispasmodics; and antidiarrheals. Further, it is involved in the contract manufacturing services. It sells its products through PharmaMart, an online platform. The company was incorporated in 2005 and is based in Lagos, Nigeria.
Investors usually follow MECURE for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Position: Non-Executive Director b. Sold 2,700,000 shares, on 26 Jan 2026. From an official NGX DirectorsDealings filing. Supporting filing text captured.
Position: Executive Director b. Bought 1,382 shares, on 23 Jan 2026. From an official NGX DirectorsDealings filing. Supporting filing text captured.
Whisone Eye extracted this official filing. Open the source to review the complete disclosure.
Director dealings
4
Reported buys, sells, and mixed dealings.
Official filings
12
Financial reports and company disclosures captured by Eye.
Market events
0
Insider, filing, dividend, and price events.
Source records
42
Captured updates we can trace.
Whisone is mixed because the bullish case is not yet strong enough to lead while turnover is thin at 0.018%. Whisone has low conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Sentiment
Market mood from flow, events, and attention.
ROE
37.8%
Return on equity
ROA
14.7%
Return on assets
Debt / equity
3.00
Lower is usually safer.
P/B ratio
10.21
Useful for book value support.
Dividend yield
0.6%
Current income signal.
76/100
Direction
Heavy downside risk
Main supports
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Volatility is elevated, so the path can stay rough even if the thesis is right.
Fair value
₦56.14
Analyst view
n/a
Forecast refresh
Updated 1h ago
Quality score
58
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
3.1
Momentum is weak and the stock is in oversold territory.
Recent trend
Falling
-40.8% across the latest saved price window.
Volatility
High
Beta is 1.76. Price may swing more than the wider market.
52-week position
46% of range
Price is sitting around the middle of its 52-week range.
Volume confirmation
1.24x average
Trading activity is above average, giving the current move stronger participation.
MECURE may benefit from credit_rating_stability. Confidence 95%.
GCR affirmed long- and short-term issuer ratings and revised the long-term outlook to Stable, citing improved competitive position, earnings, expansion and product innovation.
GCR rating affirmation
MECURE may benefit from gcr rating affirmation. Confidence 90%.
GCR affirmed long- and short-term ratings and cited MeCure's stronger competitive position, sound earnings and expansion as support for the affirmation.
GCR rating affirmation (BBB NG, Stable outlook)
MECURE may benefit from gcr rating affirmation (bbb ng, stable outlook). Confidence 90%.
GCR affirmed MeCure's long- and short-term issuer ratings and revised long-term outlook to Stable, citing improved competitive position, earnings, expansion, and innovation.
GCR rating affirmation (BBB stable / A3)
MECURE may benefit from gcr rating affirmation (bbb stable / a3). Confidence 90%.
GCR affirmed long- and short-term issuer ratings and revised the long-term outlook to Stable, citing improved competitive position, earnings, expansion and product innovation.
GCR rating affirmation (BBB, stable)
MECURE may benefit from gcr rating affirmation (bbb, stable). Confidence 90%.
Article states GCR affirmed MeCure's national-scale issuer rating at BBB with a stable outlook, implying credit stability for the company.
GCR rating affirmation (stable BBB)
MECURE may benefit from gcr rating affirmation (stable bbb). Confidence 90%.
GCR affirmed MeCure's national scale issuer ratings and maintained a stable BBB outlook for H1 2026.
Sector spillover signals
q1_2026_gdp_growth
MECURE may also move because the HEALTHCARE sector may move with q1_2026_gdp_growth. Confidence 63%.
NBS data cited in the article shows the healthcare sector grew by 1.99% in Q1 2026 (vs 1.76% in Q1 2025), indicating sector-level growth dynamics affecting listed healthcare firms.
local manufacturing / import substitution
MECURE may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
MECURE may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
MECURE may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
MECURE may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
MECURE may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
increased manufacturing capacity
MECURE may also move because the HEALTHCARE sector may benefit from increased manufacturing capacity. Confidence 53%.
Neimeth's expansion and completion of a pharmaceutical manufacturing facility will increase production capacity within the healthcare sector.
Halal certification adoption
MECURE may also move because the HEALTHCARE sector may benefit from halal certification adoption. Confidence 49%.
Halal certification can increase consumer confidence and market access where Halal-compliant products are important, supporting sector trust and accessibility.
MECURE
MeCure Industries Plc
Price: ₦56.20
P/E: 31.18
Yield: 0.6%
EKOCORP
Eko Corporation Plc
Price: ₦5.80
P/E: N/A
Yield: N/A
FIDSON
Fidson Healthcare Plc
Price: ₦93.55
P/E: 22.27
Yield: 1.6%
MAYBAKER
May & Baker Nigeria Plc
Price: ₦40.00
P/E: 12.66
Yield: 1.0%
Industry
Pharmaceutical Preparations
Founded
2005
Employees
195
Exchange
NGX
Ticker
MECURE
Estimated earnings date
2026-07-29
Estimated earnings date
2026-04-28
